Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting Medical Device Investing
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi , a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma Biotech Investing
Bristol Myers Squibb to Participate in Guggenheim's Virtual Healthcare Talks | 2021 Oncology Day Biotech Investing
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate Medical Device Investing
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020 Biotech Investing
Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness
